Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Preoperative Gabapentin for Acute and Chronic Post-thoracotomy Analgesia

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Michelle Kinney, Mayo Clinic
ClinicalTrials.gov Identifier:
NCT00588159
First received: December 18, 2007
Last updated: August 24, 2011
Last verified: August 2011
Results First Received: December 28, 2010  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Pain
Interventions: Drug: Gabapentin
Drug: Diphenhydramine

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Gabapentin Preoperatively Preoperative gabapentin 600 mg p.o. within 2 hours prior to surgery.
Active Placebo Diphenhydramine 12.5 mg p.o. 2 hours preoperatively.

Participant Flow:   Overall Study
    Gabapentin Preoperatively     Active Placebo  
STARTED     72     74  
COMPLETED     57     63  
NOT COMPLETED     15     11  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Gabapentin Preoperatively Preoperative gabapentin 600 mg p.o. within 2 hours prior to surgery.
Active Placebo Diphenhydramine 12.5 mg p.o. 2 hours preoperatively.
Total Total of all reporting groups

Baseline Measures
    Gabapentin Preoperatively     Active Placebo     Total  
Number of Participants  
[units: participants]
  72     74     146  
Age  
[units: participants]
     
<=18 years     0     0     0  
Between 18 and 65 years     33     38     71  
>=65 years     39     36     75  
Age  
[units: years]
Mean ± Standard Deviation
  64  ± 7     64  ± 7     64  ± 7  
Gender  
[units: participants]
     
Female     32     38     70  
Male     40     36     76  
Region of Enrollment  
[units: participants]
     
United States     72     74     146  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Average Pain Score at Rest   [ Time Frame: 48 hours ]

2.  Primary:   Average Pain Score With Coughing the First Morning Following Surgery   [ Time Frame: First morning following surgery ]

3.  Primary:   Average Pain Score With Coughing on Second Morning After Surgery   [ Time Frame: Second morning after surgery ]

4.  Secondary:   Opioid Consumption in First 24 Hours Postoperatively   [ Time Frame: 24 hours ]

5.  Secondary:   Number of Participants With Pain at Thoracotomy Site 3 Months Postoperatively   [ Time Frame: 3 months postoperatively ]

6.  Secondary:   Opioid Consumption in Second 24 Hour Hour Period (Hours 24-48) Postoperatively   [ Time Frame: 48 hours postoperatively ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Dr. Michelle A. O. Kinney
Organization: Mayo Clinic
phone: 507-266-9877
e-mail: kinney.michelle@mayo.edu


No publications provided by Mayo Clinic

Publications automatically indexed to this study:

Responsible Party: Michelle Kinney, Mayo Clinic
ClinicalTrials.gov Identifier: NCT00588159     History of Changes
Other Study ID Numbers: 05-004145
Study First Received: December 18, 2007
Results First Received: December 28, 2010
Last Updated: August 24, 2011
Health Authority: United States: Institutional Review Board